Scarica l'app Stockscreener
5.55
0.91%
0.05
Dopo l'orario di chiusura:
5.55
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GLUE Giù?
Forum
Previsione
Precedente Chiudi:
$5.50
Aprire:
$5.49
Volume 24 ore:
685.24K
Relative Volume:
0.80
Capitalizzazione di mercato:
$331.14M
Reddito:
-
Utile/perdita netta:
$-130.41M
Rapporto P/E:
-2.4777
EPS:
-2.24
Flusso di cassa netto:
$-67.76M
1 W Prestazione:
-4.97%
1M Prestazione:
-14.75%
6M Prestazione:
-4.64%
1 anno Prestazione:
-11.90%
Intervallo 1D:
$5.37
$5.66
Intervallo di 1 settimana:
$5.25
$6.26
Portata 52W:
$3.21
$12.40
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
Nome
Monte Rosa Therapeutics Inc
Settore
Industria
Telefono
617-949-2643
Indirizzo
321 HARRISON AVENUE, BOSTON
Confronta GLUE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
5.55 | 331.14M | 0 | -130.41M | -67.76M | -2.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-19 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-02-15 | Iniziato | Wedbush | Outperform |
| 2023-01-03 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-10-13 | Iniziato | UBS | Buy |
| 2022-08-15 | Iniziato | Jefferies | Buy |
| 2022-04-28 | Iniziato | Credit Suisse | Neutral |
| 2022-02-10 | Iniziato | Wells Fargo | Equal Weight |
| 2021-10-14 | Iniziato | SVB Leerink | Mkt Perform |
Mostra tutto
Monte Rosa Therapeutics Inc Borsa (GLUE) Ultime notizie
Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference - GlobeNewswire
Can Monte Rosa's Molecular Glue Technology Transform Drug Development? CEO Presents Latest Advances - StockTitan
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Short Interest Update - MarketBeat
Bullish On Monte Rosa Therapeutics' 'Undruggable' Targets With QuEEN (NASDAQ:GLUE) - Seeking Alpha
Janney Montgomery Scott LLC Acquires Shares of 13,315 Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
SG Americas Securities LLC Has $116,000 Stock Holdings in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
The Potential Rise in the Price of Monte Rosa Therapeutics Inc (GLUE) following insiders activity - Knox Daily
BlackRock, Inc. Increases Stake in Monte Rosa Therapeutics Inc - GuruFocus.com
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Short Interest Up 8.8% in January - MarketBeat
JPMorgan Chase & Co. Has $98,000 Stake in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Monte Rosa Therapeutics (NASDAQ:GLUE) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Vanguard Group Inc. Expands Stake in Monte Rosa Therapeutics Inc. - GuruFocus.com
Barclays PLC Acquires 43,499 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Sees Large Growth in Short Interest - Defense World
Jane Street Group LLC Sells 51,005 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Monte Rosa Therapeutics provide corporate update, key milestones 2025 - Yahoo Finance
(GLUE) Technical Data - Stock Traders Daily
Monte Rosa outlines 2025 clinical milestones - Investing.com India
Monte Rosa outlines 2025 clinical milestones By Investing.com - Investing.com Australia
Monte Rosa Therapeutics Outlines 2025 Milestones and Financial Strength - TipRanks
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025 - The Manila Times
Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Shares Acquired by Barclays PLC - Defense World
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Shares Acquired by Geode Capital Management LLC - Defense World
Geode Capital Management LLC Purchases 197,247 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - MarketBeat
State Street Corp Raises Stake in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short Term - Yahoo Finance
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Wells Fargo Downgrades Monte Rosa Therapeutics (GLUE) - MSN
Monte Rosa Therapeutics (NASDAQ:GLUE) Cut to Equal Weight at Wells Fargo & Company - MarketBeat
Charles Schwab Investment Management Inc. Boosts Stock Holdings in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
The Manufacturers Life Insurance Company Buys 15,168 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors - Marketscreener.com
Monte Rosa Therapeutics appoints new board member - Investing.com
Monte Rosa Therapeutics appoints new board member By Investing.com - Investing.com UK
Monte Rosa Therapeutics Strengthens Board with Teva's R&D Chief, Advancing Molecular Glue Platform - StockTitan
Monte Rosa reports promising cancer therapy results By Investing.com - Investing.com Nigeria
Monte Rosa reports promising cancer therapy results - Investing.com
Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders - The Manila Times
Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer - The Manila Times
Monte Rosa Therapeutics Announces Closing of Global License - GlobeNewswire
Monte Rosa Therapeutics Presents Preclinical Data at the - GlobeNewswire
Monte Rosa Secures Landmark $2.1B Novartis Deal for Revolutionary Drug Development Program - StockTitan
Intech Investment Management LLC Makes New $77,000 Investment in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
The 2nd Dimension: VC raises $500M fund for entrepreneurs pioneering life sci, tech - Fierce Biotech
Monte Rosa Therapeutics (NASDAQ:GLUE) Shares Up 8.7%Here's What Happened - MarketBeat
Monte Rosa Therapeutics Inc Azioni (GLUE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
6.45%
1.23%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):